Utah Medical Products
UTMD
78 hedge funds and large institutions have $216M invested in Utah Medical Products in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
4% more funds holding
Funds holding: 75 → 78 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.66% less ownership
Funds ownership: 70.12% → 69.47% (-0.66%)
2% less capital invested
Capital invested by funds: $220M → $216M (-$3.56M)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$903K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$394K |
| 3 |
WAM
Watershed Asset Management
San Francisco,
California
|
+$252K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$222K |
| 5 |
Invesco
Atlanta,
Georgia
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$30.1M |
| 2 |
JP Morgan Chase
New York
|
-$1.01M |
| 3 |
Renaissance Technologies
New York
|
-$958K |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$490K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$459K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
76
Credit Suisse
Zurich,
Switzerland
| $1K | +$794 | +9 | +113% |
|
|
C
77
Covestor
London,
United Kingdom
| $1K | +$1.41K | +16 | New |
|
|
78
AQR Capital Management
Greenwich,
Connecticut
| – | -$459K | -5,346 | Closed |
|
79
UBS Group
Zurich,
Switzerland
| – | -$34K | -391 | Closed |
|
80
UBS AM
Chicago,
Illinois
| – | -$3.78K | -44 | Closed |
|
81
Rockefeller Capital Management
New York
| – | -$3K | -35 | Closed |
|
|
BCM
82
Bourgeon Capital Management
Darien,
Connecticut
| – | +$265 | +3 | New |
|
UTMD Hedge Fund Activity: Q3 2022 in Review
78 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q3 2022, worth a combined $216M — down 1.6% from $220M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new UTMD positions and 4 closed out — a net gain of 3 holders — while 23 added to existing stakes and 31 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $903K. The largest seller was T. Rowe Price Associates, cutting an estimated $30.1M.
- 78 institutional investors held Utah Medical Products (UTMD) as of Q3 2022, up from 75 in Q2 2022.
- Funds reported $216M of Utah Medical Products stock for Q3 2022, down 1.6% quarter-over-quarter.
- 7 funds opened new Utah Medical Products positions in Q3 2022 and 4 closed out, a net change of +3 holders.
- The largest Utah Medical Products buyer in Q3 2022 was Goldman Sachs, an estimated $903K added.
- The largest Utah Medical Products seller in Q3 2022 was T. Rowe Price Associates, an estimated $30.1M sold.
Based on aggregated 13F filings for Q3 2022.